Huilei Yu | Biocatalysis | Research Excellence Award

Prof. Huilei Yu | Biocatalysis | Research Excellence Award

East China University of Science and Technology | China

Prof. Huilei Yu is a leading scholar in biocatalysis and bioprocess engineering and currently serves as Professor at the State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology (ECUST), Shanghai, China. She earned her Ph.D. in Biochemical Engineering from ECUST in 2008 under the mentorship of Prof. Jianhe Xu and rapidly advanced in her academic career, being appointed Associate Professor in 2010 and promoted to full Professor in 2017. From 2013–2014, she was a Visiting Professor at the Massachusetts Institute of Technology (MIT), where she expanded her work on metabolic engineering and computational enzyme design. Prof. Yu’s research is positioned at the intersection of enzyme engineering, artificial intelligence-assisted design, and sustainable biomanufacturing. Her work focuses on structure-guided rational design of enzymes, advanced AI-driven enzyme optimization, and biocatalytic synthesis of high-value chemicals including chiral sulfoxides, hydroxy acids, and pharmaceutical intermediates. Her research has pioneered next-generation enzyme engineering frameworks that integrate molecular modeling, machine learning, and catalytic mechanism elucidation to achieve improved substrate adaptability, stability, selectivity, and process efficiency. She has authored numerous high-impact publications in journals such as Angewandte Chemie, Science Advances, ACS Catalysis, ChemSusChem, and Organic Process Research & Development. Several of her enzyme-based catalytic systems have been successfully transferred to industrial practice, contributing to waste minimization, carbon reduction, and greener pharmaceutical synthesis. Her methodologies for enantioselective synthesis of chiral sulfoxides and alcohols are particularly recognized for reducing solvent usage and enabling scalable industrial applicability. Prof. Yu serves as Executive Editor of Bioresources and Bioprocessing and actively participates in international scientific societies and collaborative consortia. Her contributions have been recognized through multiple awards, including Outstanding Academic Leader of Shanghai, Outstanding Young Enzymologist Award, and the First-Level Technical Innovation Award of Shanghai. Through interdisciplinary leadership, impactful innovation, and translational research achievements, Prof. Huilei Yu continues to shape the global landscape of enzyme biotechnology and sustainable chemical manufacturing.

Profile: Scopus 

Featured Publications

  1. Multiple Authors (2025). Hinge loop reconstruction facilitates hydride transfer in Baeyer-Villiger monooxygenases.

  2. Multiple Authors (2025). Engineering an unspecific peroxygenase from Thielavia terrestris for specific terminal oxidation of xylene derivatives.

  3. Multiple Authors (2025). Flipping of a non-productive substrate binding conformation facilitates hydroxynitrile lyase catalyzed hydrocyanation.

  4. Multiple Authors (2025). Reprogramming the catalytic pocket of Baeyer–Villiger monooxygenase for environmentally compatible synthesis of a chiral sulfoxide pharmaceutical.

  5. Multiple Authors (2025). An engineered meso-diaminopimelate dehydrogenase enables the biocatalytic synthesis of bulky β-substituted D-amino acids.

Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Assist. Prof. Dr. Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Faculty Member from Neyshabur university of medical sciences, Iran

Dr. Amir Abbas Momtazi-Borojeni is an Assistant Professor of Medical Biotechnology at Neyshabur University of Medical Sciences in Iran. Born on September 17, 1985, in Isfahan, Iran, he has established a distinguished career in medical biotechnology, focusing on nanomedicine, immunotherapy, and phytomedicine. With over 160 publications and more than 7,000 citations, his research has significantly contributed to the fields of cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies and nanoliposomal drug delivery systems has been recognized internationally. Dr. Momtazi-Borojeni’s interdisciplinary approach integrates molecular biology, pharmacology, and bioinformatics, reflecting his commitment to advancing medical science through innovative research.

Professional Profile​

Education

Dr. Momtazi-Borojeni’s academic journey began with a BSc in Biology from Isfahan University (2004–2008), followed by an MSc in Microbial Biotechnology from the same institution (2008–2010). He then pursued a Ph.D. in Medical Biotechnology at Mashhad University of Medical Sciences (2013–2019), where his research focused on developing nanoliposome-based vaccines targeting PCSK9 for lipid-lowering and anti-atherosclerotic effects. His doctoral work combined immunology, nanotechnology, and cardiovascular research, laying the foundation for his future contributions to medical biotechnology.

Professional Experience

Dr. Momtazi-Borojeni has held various research and academic positions, including roles as a genomics lab expert at the Biotechnology Research Institute in Esfahan and as a part-time researcher at the Pharmaceutical Sciences Research Center of Isfahan University of Medical Sciences. He has also taught courses in cellular and molecular biology, genetic engineering, and bioinformatics at Isfahan University and Islamic Azad University, Neyshabur branch. Currently, he serves as an Assistant Professor at Neyshabur University of Medical Sciences, where he continues to advance research in medical biotechnology.

Research Interests

Dr. Momtazi-Borojeni’s research interests encompass nanomedicine, immunotherapy, and phytomedicine, with a particular focus on developing innovative treatments for cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies, including vaccine development and siRNA delivery systems, aims to provide alternative strategies for managing hypercholesterolemia and atherosclerosis. Additionally, he explores the therapeutic potential of natural compounds and bioinformatics approaches to identify novel drug targets and understand disease mechanisms.

Research Skills

Dr. Momtazi-Borojeni possesses a diverse skill set that includes expertise in nanotechnology-based drug delivery, molecular biology techniques, immunological assays, and bioinformatics analysis. His proficiency in designing and characterizing nanoliposomes, conducting in vivo studies, and analyzing gene expression profiles enables him to undertake complex research projects that bridge multiple disciplines. His collaborative work with international researchers further demonstrates his ability to contribute to multidisciplinary teams and advance scientific knowledge.

Awards and Honors

While specific awards and honors are not detailed in the provided information, Dr. Momtazi-Borojeni’s extensive publication record and citation metrics reflect his significant impact on the field of medical biotechnology. His research has been published in reputable journals, and his contributions to the development of PCSK9-targeted therapies have garnered international recognition. His active participation in scientific communities and collaborations with researchers worldwide underscore his commitment to advancing medical science.

Conclusion

Dr. Amir Abbas Momtazi-Borojeni’s extensive research in medical biotechnology, particularly in the areas of nanomedicine and immunotherapy, positions him as a strong candidate for the Best Researcher Award. His innovative approaches to treating cardiovascular and metabolic diseases, combined with his interdisciplinary expertise and collaborative spirit, have significantly advanced the field. While specific awards and honors are not listed, his prolific publication record and international collaborations attest to his contributions to medical science. Continued support for his research endeavors will likely yield further breakthroughs in therapeutic strategies and enhance our understanding of complex diseases.

Publications Top Notes

  1. Therapeutic effects of curcumin in inflammatory and immune‐mediated diseases: A nature‐made jack‐of‐all‐trades?

    • Authors: E. Abdollahi, A.A. Momtazi, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 302

  2. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial

    • Authors: Y. Panahi, N. Khalili, E. Sahebi, S. Namazi, L.E. Simental-Mendía, M. Majeed, A. Sahebkar

    • Year: 2018

    • Citations: 257

  3. Curcumin as a MicroRNA regulator in cancer: a review

    • Authors: A.A. Momtazi, F. Shahabipour, S. Khatibi, T.P. Johnston, M. Pirro, A. Sahebkar

    • Year: 2016

    • Citations: 256

  4. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus

    • Authors: A.A. Momtazi-Borojeni, S.M. Haftcheshmeh, S.A. Esmaeili, T.P. Johnston, A. Sahebkar

    • Year: 2018

    • Citations: 233

  5. Isolation, identification, and characterization of cancer stem cells: A review

    • Authors: M.R. Abbaszadegan, V. Bagheri, M.S. Razavi, A.A. Momtazi, A. Sahebkar

    • Year: 2017

    • Citations: 228

  6. Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity

    • Authors: R. Rezaee, A.A. Momtazi, A. Monemi, A. Sahebkar

    • Year: 2017

    • Citations: 199

  7. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease

    • Authors: A.S. Moghaddam, J.T. Afshari, S.A. Esmaeili, E. Saburi, Z. Joneidi, A. Sahebkar

    • Year: 2019

    • Citations: 196

  8. A review on the pharmacology and toxicology of steviol glycosides extracted from Stevia rebaudiana

    • Authors: A. Abbas Momtazi-Borojeni, S.A. Esmaeili, E. Abdollahi, A. Sahebkar

    • Year: 2017

    • Citations: 192

  9. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases

    • Authors: A.A. Momtazi, G. Derosa, P. Maffioli, M. Banach, A. Sahebkar

    • Year: 2016

    • Citations: 186

  10. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile

    • Authors: A. Abbas Momtazi, A. Sahebkar

    • Year: 2016

    • Citations: 178